

Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the prospectus dated June 29, 2022 (the “**Prospectus**”) issued by MicroPort NeuroTech Limited (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares thereby offered.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in Hong Kong, the United States or elsewhere. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended, supplemented or otherwise modified from time to time (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities by the Company in the United States.

In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as stabilization manager (the “**Stabilization Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilization Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on Sunday, August 7, 2022, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Sunday, August 7, 2022, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.



**MicroPort NeuroTech Limited**

**微創腦科學有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

## GLOBAL OFFERING

<b>Number of Offer Shares under the Global Offering</b>	<b>: 13,700,000 Offer Shares (subject to the Over-allotment Option)</b>
<b>Number of Hong Kong Offer Shares</b>	<b>: 1,370,000 Offer Shares (subject to adjustment)</b>
<b>Number of International Offer Shares</b>	<b>: 12,330,000 Offer Shares (including 685,000 Reserved Shares under the Preferential Offering) (subject to adjustment and the Over-allotment Option)</b>
<b>Offer Price</b>	<b>: HK\$24.64 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)</b>
<b>Nominal Value</b>	<b>: US\$0.00002 per Share</b>
<b>Stock Code</b>	<b>: 2172</b>

*Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*

**J.P.Morgan**

**CICC 中金公司**

*Joint Bookrunners and Joint Lead Managers*

**富途證券**

**利弗莫尔证券**  
LIVERMORE HOLDINGS LIMITED

**IMPORTANT NOTICE TO INVESTORS:  
FULLY ELECTRONIC APPLICATION PROCESS**

**We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the Prospectus or printed copies of any application forms to the public in relation to the Hong Kong Public Offering.**

**The Prospectus is available at the website of the Hong Kong Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) under the “*HKEXnews > New Listings > New Listing Information*” section, and our website at [www.medneurotech.com](http://www.medneurotech.com). If you require a printed copy of the Prospectus, you may download and print from the website addresses above.**

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online through the **White Form eIPO** service at [www.eipo.com.hk](http://www.eipo.com.hk); or
- (2) apply through the **CCASS EIPO** service to electronically cause HKSCC Nominees to apply on your behalf, including by:
  - (i) instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf; or
  - (ii) (if you are an existing **CCASS Investor Participant**) giving **electronic application instructions** through the CCASS Internet System (<https://ip.ccass.com>) or through the CCASS Phone System by calling +852 2979 7888 (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input **electronic application instructions** for CCASS Investor Participants through HKSCC’s Customer Service Centre at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong by completing an input request.

If you have any question about the application for the Hong Kong Offer Shares, you may call the enquiry hotline of our Hong Kong Share Registrar and **White Form eIPO** Service Provider, Computershare Hong Kong Investor Services Limited, both at +852 2862 8646 on the following dates:

Wednesday, June 29, 2022 — 9:00 a.m. to 9:00 p.m.  
Thursday, June 30, 2022 — 9:00 a.m. to 9:00 p.m.  
Monday, July 4, 2022 — 9:00 a.m. to 9:00 p.m.  
Tuesday, July 5, 2022 — 9:00 a.m. to 9:00 p.m.  
Wednesday, July 6, 2022 — 9:00 a.m. to 9:00 p.m.  
Thursday, July 7, 2022 — 9:00 a.m. to 9:00 p.m.  
Friday, July 8, 2022 — 9:00 a.m. to 12:00 noon

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed Prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

If you are an **intermediary, broker or agent**, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses above.

Please refer to the section headed “How to Apply for Hong Kong Offer Shares and Reserved Shares” in the Prospectus for further details on the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **White Form eIPO** service or by giving **electronic application instructions** to HKSCC must be for a minimum of 1,000 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.

**MicroPort NeuroTech Limited**  
(HK\$24.64 per Hong Kong Offer Share)

**NUMBER OF HONG KONG OFFER SHARES THAT MAY BE APPLIED FOR AND PAYMENTS**

No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>	No. of Hong Kong Offer Shares applied for	Amount payable on application <i>HK\$</i>
1,000	24,888.34	12,000	298,660.00	50,000	1,244,416.71	200,000	4,977,666.85
2,000	49,776.66	14,000	348,436.68	60,000	1,493,300.06	250,000	6,222,083.56
3,000	74,665.01	16,000	398,213.34	70,000	1,742,183.40	300,000	7,466,500.27
4,000	99,553.34	18,000	447,990.03	80,000	1,991,066.74	350,000	8,710,916.99
5,000	124,441.67	20,000	497,766.69	90,000	2,239,950.09	400,000	9,955,333.69
6,000	149,330.00	25,000	622,208.35	100,000	2,488,833.43	450,000	11,199,750.41
7,000	174,218.34	30,000	746,650.03	120,000	2,986,600.11	500,000	12,444,167.12
8,000	199,106.68	35,000	871,091.69	140,000	3,484,366.79	550,000	13,688,583.83
9,000	223,995.01	40,000	995,533.37	160,000	3,982,133.47	600,000	14,933,000.55
10,000	248,883.34	45,000	1,119,975.04	180,000	4,479,900.16	685,000 <sup>(1)</sup>	17,048,508.96

(1) Maximum number of Hong Kong Offer Shares you may apply for.

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

Qualifying MicroPort Shareholders who would like to be allotted the Reserved Shares under the Preferential Offering should complete and sign the **BLUE** Application Forms.

**Application for the Hong Kong Offer Shares and Reserved Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the relevant Application Forms and the designated website ([www.eipo.com.hk](http://www.eipo.com.hk)) for White Form eIPO.**

A **BLUE** Application Form (if the related Qualifying MicroPort Shareholders have elected to receive corporate communications in printed form) has been dispatched to each Qualifying MicroPort Shareholder on or before Wednesday, June 29, 2022. Electronic copies of the Prospectus can be viewed from the respective websites of the Company at [www.medneurotech.com](http://www.medneurotech.com) and the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) under the section headed “*HKEXnews > Listed Company Publications > Latest Listed Company Information*”.

Qualifying MicroPort Shareholders who require a replacement **BLUE** Application Form should contact Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong or on its hotline +852 2862 8555.

## **THE LISTING APPLICATION**

The Company has applied to the Stock Exchange for the listing of, and permission to deal in, the Shares to be issued pursuant to the Global Offering (including any Shares to be issued pursuant to the exercise of the Over-allotment Option).

## **STRUCTURE OF THE GLOBAL OFFERING**

The Global Offering comprises:

- the Hong Kong Public Offering of initially 1,370,000 Shares (subject to adjustment) representing 10.0% of the total number of Offer Shares initially available under the Global Offering; and
- the International Offering of initially 12,330,000 Shares (subject to adjustment and the Over-allotment Option) representing 90.0% of the total number of Offer Shares initially available under the Global Offering.

Of the 12,330,000 Offer Shares initially being offered under the International Offering, 685,000 Offer Shares (representing approximately 5.56% and 5.00% of the Offer Shares initially being offered under the International Offering and the Global Offering, respectively) will be offered to the Qualifying MicroPort Shareholders as an Assured Entitlement by way of the Preferential Offering.

The allocation of the Offer Shares between the International Offering and the Hong Kong Public Offering, in each case, will be subject to reallocation on the basis as described in the section headed “Structure of the Global Offering” in the Prospectus. The Reserved Shares are not subject to such reallocation. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to the clawback mechanism as set out in Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares that may be allocated to the Hong Kong Public Offering following such reallocation shall be not more than double the initial allocation to the Hong Kong Public Offering (i.e. 2,740,000 Shares, representing 20.00% of the total number of Offer Shares initially available under the Global Offering).

In connection with the Global Offering, the Company is expected to grant the Over-allotment Option to the International Underwriters, which will be exercisable by the Joint Global Coordinators (for themselves and on behalf of the International Underwriters) at any time from the Listing Date to the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering (being Sunday, August 7, 2022). Pursuant to the Over-allotment Option, the Company may be required to allot and issue up to an aggregate of 2,055,000 additional Shares, representing 15% of the Offer Shares initially available under the Global Offering, at the Offer Price, to cover over-allocation in the International Offering, if any. In the event the Over-allotment Option is exercised, the number of Reserved Shares will not change.

Assuming that the Global Offering becomes unconditional and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised at or before 8:00 a.m. in Hong Kong on Friday, July 15, 2022, it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on Friday, July 15, 2022 (Hong Kong time). In the event that the Over-allotment Option is exercised, an announcement will be made by the Company on the websites of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company at [www.medneurotech.com](http://www.medneurotech.com).

## **PRICING**

The Offer Price will be HK\$24.64 per Offer Share unless otherwise announced as further explained in the section headed “Structure of the Global Offering” in the Prospectus. Applicants for the Hong Kong Offer Shares are required to pay, on application, the Offer Price of HK\$24.64 per Offer Share together with brokerage fee of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%.

## **EXPECTED TIMETABLE**

Dispatch of <b>BLUE</b> Application Forms to Qualifying MicroPort Shareholders .....	Wednesday, June 29, 2022
Hong Kong Public Offering and Preferential Offering commence .....	9:00 a.m. on Wednesday, June 29, 2022
Latest time to complete electronic applications under <b>White Form eIPO</b> service through the designated website <a href="http://www.eipo.com.hk">www.eipo.com.hk</a> .....	11:30 a.m. on Friday, July 8, 2022
Application lists of the Hong Kong Public Offering and the Preferential Offering open .....	11:45 a.m. on Friday, July 8, 2022

Latest time to lodge **BLUE** Application Forms . . . . . 12:00 noon on  
Friday, July 8, 2022

Latest time for (a) completing payment of **White Form eIPO**  
applications by effecting internet banking transfer(s) or  
PPS payment transfer(s) and (b) giving  
**electronic application instructions** to HKSCC . . . . . 12:00 noon on  
Friday, July 8, 2022

If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Application lists of the Hong Kong Public Offering and  
the Preferential Offering close . . . . . 12:00 noon on  
Friday, July 8, 2022

(1) Announcement of the level of indications  
of interest in the International Offering, the level of  
applications in the Hong Kong Public Offering and  
the Preferential Offering, and the basis of allocation  
of the Hong Kong Offer Shares under the Hong Kong  
Public Offering and the Preferential Offering to be  
published on the websites of the Stock Exchange at  
[www.hkexnews.hk](http://www.hkexnews.hk) and our Company at  
[www.medneurotech.com](http://www.medneurotech.com) on or before . . . . . Thursday, July 14, 2022

(2) Announcement of results allocations in the  
Hong Kong Public Offering and the Preferential Offering  
(with successful applicants' identification document  
numbers, where appropriate) to be available through  
a variety of channels as described in the section headed  
"How to Apply for Hong Kong Offer Shares  
and Reserved Shares — E. Publication of Results"  
in the Prospectus . . . . . Thursday, July 14, 2022

(3) A full announcement of the Hong Kong Public Offering  
and the Preferential Offering containing (1) and (2) above  
to be published on the website of the Stock Exchange  
at [www.hkexnews.hk](http://www.hkexnews.hk) and our Company's website at  
[www.medneurotech.com](http://www.medneurotech.com) from . . . . . Thursday, July 14, 2022



Results of allocation for the Hong Kong Public Offering and the Preferential Offering will be available at [www.iporesults.com.hk](http://www.iporesults.com.hk) (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a “search by ID” function from . . . . . 8:00 a.m. on Thursday, July 14, 2022 to 12:00 midnight on Wednesday, July 20, 2022

The allocation results telephone enquiry by calling +852 2862 8555 between . . . . . 9:00 a.m. and 6:00 p.m. from Thursday, July 14, 2022 to Tuesday, July 19, 2022 (excluding Saturday and Sunday or public holiday in Hong Kong)

Share certificates in respect of wholly or partially successful applications to be dispatched/collected or deposited into CCASS pursuant to the Hong Kong Public Offering and the Preferential Offering on or before . . . . . Thursday, July 14, 2022

**White Form** e-Refund payment instructions/refund cheques in respect of wholly or partially successful applications (if applicable) or wholly or partially unsuccessful applications pursuant to the Hong Kong Public Offering and the Preferential Offering to be dispatched/collected on or before . . . . . Thursday, July 14, 2022

Dealings in the Shares on the Stock Exchange expected to commence at 9:00 a.m. on . . . . . Friday, July 15, 2022

## SETTLEMENT

Subject to the granting of the approval for listing of, and permission to deal in, the Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Stock Exchange or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS. Investors should seek the advice of their stockbrokers or other professional advisers for details of the settlement arrangement as such arrangements may affect their rights and interests.

## ELECTRONIC APPLICATION CHANNELS

### White Form eIPO

You may submit your application to the designated **White Form eIPO** Service Provider at [www.eipo.com.hk](http://www.eipo.com.hk) (24 hours daily, except on the last application day) from 9:00 a.m. on Wednesday, June 29, 2022 until 11:30 a.m. on Friday, July 8, 2022 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Friday, July 8, 2022 or such later time under the section headed “How to Apply for Hong Kong Offer Shares and Reserved Shares — D. Effect of Bad Weather on the Opening and Closing of the Application Lists” in the Prospectus.

### CCASS EIPO<sup>(1)</sup>

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:

Wednesday, June 29, 2022	—	9:00 a.m. to 8:30 p.m.
Thursday, June 30, 2022	—	8:00 a.m. to 8:30 p.m.
Monday, July 4, 2022	—	8:00 a.m. to 8:30 p.m.
Tuesday, July 5, 2022	—	8:00 a.m. to 8:30 p.m.
Wednesday, July 6, 2022	—	8:00 a.m. to 8:30 p.m.
Thursday, July 7, 2022	—	8:00 a.m. to 8:30 p.m.
Friday, July 8, 2022	—	8:00 a.m. to 12:00 noon

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Wednesday, June 29, 2022 until 12:00 noon on Friday, July 8, 2022 (24 hours daily, except on Friday, July 8, 2022, the last application day).

The latest time for inputting your **electronic application instructions** will be 12:00 noon on Friday, July 8, 2022, the last day for applications, or such later time as described in the section headed “How to Apply for Hong Kong Offer Shares and Reserved Shares — D. Effect of Bad Weather on the Opening and Closing of the Application Lists” in the Prospectus.

*Note:*

- (1) These times are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants and/or CCASS Investor Participants.

## PHYSICAL APPLICATION CHANNEL FOR PREFERENTIAL OFFERING

### BLUE Application Form

Qualifying MicroPort Shareholders who would like to be allotted the Reserved Shares under the Preferential Offering should complete and sign the **BLUE** Application Forms.

The completed **BLUE** Application Form, together with a check or a banker's cashier order attached and marked payable to "**BANK OF CHINA (HONG KONG) NOMINEES LIMITED — MICROPORT NEUROTECH PREFERENTIAL OFFER**" for the payment, should be deposited in the special collection boxes provided at Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong at the following times:

Wednesday, June 29, 2022 — 9:00 a.m. to 4:30 p.m.  
Thursday, June 30, 2022 — 9:00 a.m. to 4:30 p.m.  
Monday, July 4, 2022 — 9:00 a.m. to 4:30 p.m.  
Tuesday, July 5, 2022 — 9:00 a.m. to 4:30 p.m.  
Wednesday, July 6, 2022 — 9:00 a.m. to 4:30 p.m.  
Thursday, July 7, 2022 — 9:00 a.m. to 4:30 p.m.  
Friday, July 8, 2022 — 9:00 a.m. to 12:00 noon

The application monies (including brokerage, SFC transaction levy, FRC transaction levy and the Stock Exchange trading fee) will be held by the receiving banks and on behalf of the Company after the closing of the application lists and the refund monies, if any, will be returned to the applicants without interest on or before Thursday, July 14, 2022.

Please refer to the sections headed "Structure of the Global Offering" and "How to Apply for Hong Kong Offer Shares and Reserved Shares" of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

## PUBLICATION OF RESULTS

The Company expects to announce the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the Preferential Offering and the basis of allocation of the Hong Kong Offer Shares and the Reserved Shares on Thursday, July 14, 2022 on the Company's website at [www.medneurotech.com](http://www.medneurotech.com) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering and the Preferential Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed "How to Apply for Hong Kong Offer Shares and Reserved Shares — E. Publication of Results" in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Hong Kong Public Offering are not fulfilled in accordance with "Structure of the Global Offering" in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, FRC transaction levy and the Stock Exchange trading fee, will be refunded, without interest or the cheque or banker's cashier order will not be cleared.

The Company will not issue temporary documents of title or receipt for application fees received. Share certificates will only become valid at 8:00 a.m. on Friday, July 15, 2022, provided that the Global Offering has become unconditional and the right of termination described in the section headed "Underwriting" in the Prospectus has not been exercised.

Assuming the Global Offering becomes unconditional and the right of termination described in the section head "Underwriting" in the Prospectus has not been exercised at or before 8:00 a.m. on Friday, July 15, 2022, dealings in the Shares are expected to commence at 9:00 a.m. on Friday, July 15, 2022. The Shares will be traded in board lots of 1,000 Shares each. The stock code of the Shares is 2172.

*This announcement is available for viewing on the website of the Company at [www.medneurotech.com](http://www.medneurotech.com) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).*

By order of the Board  
**MicroPort NeuroTech Limited**  
微創腦科學有限公司  
**Mr. Peng Bo**  
Chairman

Hong Kong, June 29, 2022

*As at the date of this announcement, the executive Directors are Mr. Xie Zhiyong and Mr. Wang Yiquan Bruce, the non-executive Directors are Mr. Peng Bo, Mr. Wang Lin and Ms. Wu Xia, and the independent non-executive Directors are Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung.*